Acorda Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
336,430.00
401,480.00
492,660.00
519,601.00
588,287.00
471,433
Cost of Goods Sold (COGS) incl. D&A
66,643.00
80,615.00
92,931.00
108,109.00
135,714.00
99,310
Gross Income
269,787.00
320,865.00
399,729.00
411,492.00
452,573.00
372,123
SG&A Expense
238,573.00
268,466.00
354,839.00
421,274.00
343,012.00
285,121
EBIT
31,214.00
52,399.00
44,890.00
9,782.00
109,561.00
87,002
Unusual Expense
1,031.00
16,155.00
10,900.00
26,200.00
345,909.00
56,316
Non Operating Income/Expense
182.00
379.00
411.00
9,902.00
2,991.00
7,816
Interest Expense
2,170.00
9,288.00
15,472.00
16,527.00
18,664.00
21,597
Pretax Income
28,863.00
28,009.00
19,369.00
42,268.00
251,885.00
20,423
Income Tax
12,422.00
10,337.00
8,311.00
6,665.00
28,526.00
13,259
Consolidated Net Income
16,441.00
17,672.00
11,058.00
35,603.00
223,359.00
33,682
Net Income
16,441.00
17,672.00
11,058.00
34,618.00
223,359.00
33,682
Net Income After Extraordinaries
16,441.00
17,672.00
11,058.00
34,618.00
223,359.00
33,682
Net Income Available to Common
16,441.00
17,672.00
11,058.00
34,618.00
223,359.00
33,682
EPS (Basic)
0.39
0.42
0.25
0.76
4.86
0.71
Basic Shares Outstanding
40,208.00
41,150.00
42,230.00
45,259.00
45,999.00
47,010
EPS (Diluted)
0.39
0.42
0.25
0.76
4.86
0.71
Diluted Shares Outstanding
41,682.00
42,544.00
43,621.00
45,259.00
45,999.00
47,341
EBITDA
38,213.00
60,872.00
59,902.00
11,800.00
145,661.00
98,481
Non-Operating Interest Income
668.00
674.00
440.00
339.00
136.00
3,518
Minority Interest Expense
-
-
-
985.00
-
-
About Acorda Therapeutics
View Profile
